Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 424

1.

Variable radiologic lung nodule evaluation leads to divergent management recommendations.

Nair A, Bartlett EC, Walsh SLF, Wells AU, Navani N, Hardavella G, Bhalla S, Calandriello L, Devaraj A, Goo JM, Klein JS, MacMahon H, Schaefer-Prokop C, Seo JB, Sverzellati N, Desai SR; Lung Nodule Evaluation Group (Collaborators).

Eur Respir J. 2018 Nov 8. pii: 1801359. doi: 10.1183/13993003.01359-2018. [Epub ahead of print]

PMID:
30409817
2.

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice.

Fletcher SV, Jones MG, Renzoni EA, Parfrey H, Hoyles RK, Spinks K, Kokosi M, Kwok A, Warburton C, Titmuss V, Thillai M, Simler N, Maher TM, Brereton CJ, Chua F, Wells AU, Richeldi L, Spencer LG.

ERJ Open Res. 2018 Oct 19;4(4). pii: 00049-2018. doi: 10.1183/23120541.00049-2018. eCollection 2018 Oct.

3.

Sarcoidosis: A benign disease or a culture of neglect?

Wells AU.

Respir Med. 2018 Nov;144S:S1-S2. doi: 10.1016/j.rmed.2018.10.004. Epub 2018 Oct 6. No abstract available.

PMID:
30336997
4.

Author Correction: Major lung complications of systemic sclerosis.

Denton CP, Wells AU, Coghlan JG.

Nat Rev Rheumatol. 2018 Nov;14(11):682. doi: 10.1038/s41584-018-0108-3.

PMID:
30317249
5.

Efficacy data in treatment extension studies of idiopathic pulmonary fibrosis: interpret with caution.

Wells AU.

Lancet Respir Med. 2018 Sep 14. pii: S2213-2600(18)30385-0. doi: 10.1016/S2213-2600(18)30385-0. [Epub ahead of print] No abstract available.

PMID:
30224324
6.

IPF diagnosis: flexibility is a virtue.

Wells AU.

Lancet Respir Med. 2018 Oct;6(10):735-737. doi: 10.1016/S2213-2600(18)30374-6. Epub 2018 Sep 14. No abstract available. Erratum in: Lancet Respir Med. 2018 Oct;6(10):e53.

PMID:
30224321
7.

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.

Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ; INSTAGE Investigators.

N Engl J Med. 2018 Nov 1;379(18):1722-1731. doi: 10.1056/NEJMoa1811737. Epub 2018 Sep 15.

PMID:
30220235
8.

Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial.

Visca D, Mori L, Tsipouri V, Fleming S, Firouzi A, Bonini M, Pavitt MJ, Alfieri V, Canu S, Bonifazi M, Boccabella C, De Lauretis A, Stock CJW, Saunders P, Montgomery A, Hogben C, Stockford A, Pittet M, Brown J, Chua F, George PM, Molyneaux PL, Margaritopoulos GA, Kokosi M, Kouranos V, Russell AM, Birring SS, Chetta A, Maher TM, Cullinan P, Hopkinson NS, Banya W, Whitty JA, Adamali H, Spencer LG, Farquhar M, Sestini P, Wells AU, Renzoni EA.

Lancet Respir Med. 2018 Oct;6(10):759-770. doi: 10.1016/S2213-2600(18)30289-3. Epub 2018 Aug 28.

PMID:
30170904
9.

The Clinical Significance of Body Weight Loss in Idiopathic Pulmonary Fibrosis Patients.

Nakatsuka Y, Handa T, Kokosi M, Tanizawa K, Puglisi S, Jacob J, Sokai A, Ikezoe K, Kanatani KT, Kubo T, Tomioka H, Taguchi Y, Nagai S, Chin K, Mishima M, Wells AU, Hirai T.

Respiration. 2018;96(4):338-347. doi: 10.1159/000490355. Epub 2018 Aug 21.

PMID:
30130749
10.

Major lung complications of systemic sclerosis.

Denton CP, Wells AU, Coghlan JG.

Nat Rev Rheumatol. 2018 Sep;14(9):511-527. doi: 10.1038/s41584-018-0062-0. Review. Erratum in: Nat Rev Rheumatol. 2018 Nov;14(11):682.

PMID:
30111804
11.

Sarcoidosis: is cryobiopsy not cool enough? - Authors' reply.

Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU.

Lancet Respir Med. 2018 Sep;6(9):e45. doi: 10.1016/S2213-2600(18)30217-0. Epub 2018 Jul 11. No abstract available.

PMID:
30007850
12.

Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis: The Future of Quantitative Analysis.

Wu X, Kim GH, Salisbury ML, Barber D, Bartholmai BJ, Brown KK, Conoscenti CS, De Backer J, Flaherty KR, Gruden JF, Hoffman EA, Humphries SM, Jacob J, Maher TM, Raghu G, Richeldi L, Ross BD, Schlenker-Herceg R, Sverzellati N, Wells AU, Martinez FJ, Lynch DA, Goldin J, Walsh SLF.

Am J Respir Crit Care Med. 2018 Jul 9. doi: 10.1164/rccm.201803-0444PP. [Epub ahead of print]

13.

Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry.

Baughman RP, Shlobin OA, Wells AU, Alhamad EH, Culver DA, Barney J, Cordova FC, Carmona EM, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS, Kouranos V, O'Hare L, Baran JM, Cal JG, Lower EE, Engel PJ, Nathan SD.

Respir Med. 2018 Jun;139:72-78. doi: 10.1016/j.rmed.2018.04.015. Epub 2018 May 5.

PMID:
29858005
14.

What's in a name? That which we call IPF, by any other name would act the same.

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group.

Eur Respir J. 2018 May 17;51(5). pii: 1800692. doi: 10.1183/13993003.00692-2018. Print 2018 May.

PMID:
29773608
15.

Functional associations of pleuroparenchymal fibroelastosis and emphysema with hypersensitivity pneumonitis.

Jacob J, Odink A, Brun AL, Macaluso C, de Lauretis A, Kokosi M, Devaraj A, Desai S, Renzoni E, Wells AU.

Respir Med. 2018 May;138:95-101. doi: 10.1016/j.rmed.2018.03.031. Epub 2018 Mar 30.

16.

Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design.

Behr J, Nathan SD, Harari S, Wuyts W, Kirchgaessler KU, Bengus M, Gilberg F, Wells AU.

Respir Med. 2018 May;138:13-20. doi: 10.1016/j.rmed.2018.03.019. Epub 2018 Mar 16.

17.

Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis.

Jacob J, Bartholmai BJ, Rajagopalan S, van Moorsel CHM, van Es HW, van Beek FT, Struik MHL, Kokosi M, Egashira R, Brun AL, Nair A, Walsh SLF, Cross G, Barnett J, de Lauretis A, Judge EP, Desai S, Karwoski R, Ourselin S, Renzoni E, Maher TM, Altmann A, Wells AU.

Am J Respir Crit Care Med. 2018 Sep 15;198(6):767-776. doi: 10.1164/rccm.201711-2174OC.

18.

Personalised medicine in interstitial lung diseases: Number 6 in the Series "Personalised medicine in respiratory diseases" Edited by Renaud Louis and Nicolas Roche.

Kokosi MA, Margaritopoulos GA, Wells AU.

Eur Respir Rev. 2018 Apr 13;27(148). pii: 170117. doi: 10.1183/16000617.0117-2017. Print 2018 Jun 30. Review.

19.

Pulmonary sarcoidosis.

Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU.

Lancet Respir Med. 2018 May;6(5):389-402. doi: 10.1016/S2213-2600(18)30064-X. Epub 2018 Apr 3. Review.

PMID:
29625772
20.

Rapidly Progressive Cystic Lung Disease.

Rogers C, Kent-Bramer J, Devaraj A, Nicholson AG, Molyneaux PL, Wells AU, Saikia S, Maher TM, George PM.

Am J Respir Crit Care Med. 2018 Jul 15;198(2):264. doi: 10.1164/rccm.201801-0161IM. No abstract available.

21.

Diagnostic Ability of a Dynamic Multidisciplinary Discussion in Interstitial Lung Diseases: A Retrospective Observational Study of 938 Cases.

De Sadeleer LJ, Meert C, Yserbyt J, Slabbynck H, Verschakelen JA, Verbeken EK, Weynand B, De Langhe E, Lenaerts JL, Nemery B, Van Raemdonck D, Verleden GM, Wells AU, Wuyts WA.

Chest. 2018 Jun;153(6):1416-1423. doi: 10.1016/j.chest.2018.03.026. Epub 2018 Mar 30.

PMID:
29608882
22.

Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease.

Jacob J, Song JW, Yoon HY, Cross G, Barnett J, Woo WL, Adams F, Kokosi M, Devaraj A, Renzoni E, Maher TM, Kim DS, Wells AU.

EBioMedicine. 2018 Feb;28:303-310. doi: 10.1016/j.ebiom.2018.01.038. Epub 2018 Jan 31.

23.

Validation of multidisciplinary diagnosis in IPF.

Castillo D, Walsh S, Hansell DM, Vasakova M, Cottin V, Altinisik G, Palmucci S, Sterclova M, Harari S, Richeldi L, Vancheri C, Wells AU; ERICE ILD working group.

Lancet Respir Med. 2018 Feb;6(2):88-89. doi: 10.1016/S2213-2600(18)30023-7. Review. No abstract available.

PMID:
29413085
24.

Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization.

Keir GJ, Wort SJ, Kokosi M, George PM, Walsh SLF, Jacob J, Price L, Bax S, Renzoni EA, Maher TM, MacDonald P, Hansell DM, Wells AU.

Respirology. 2018 Jul;23(7):687-694. doi: 10.1111/resp.13250. Epub 2018 Jan 12.

PMID:
29327393
25.

Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis: impact on therapy.

George PM, Wells AU.

Expert Rev Clin Immunol. 2018 Feb;14(2):127-135. doi: 10.1080/1744666X.2018.1427064. Epub 2018 Jan 20.

PMID:
29320306
26.

Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure.

Hetzel J, Maldonado F, Ravaglia C, Wells AU, Colby TV, Tomassetti S, Ryu JH, Fruchter O, Piciucchi S, Dubini A, Cavazza A, Chilosi M, Sverzellati N, Valeyre D, Leduc D, Walsh SLF, Gasparini S, Hetzel M, Hagmeyer L, Haentschel M, Eberhardt R, Darwiche K, Yarmus LB, Torrego A, Krishna G, Shah PL, Annema JT, Herth FJF, Poletti V.

Respiration. 2018;95(3):188-200. doi: 10.1159/000484055. Epub 2018 Jan 9.

27.

Upregulation of citrullination pathway: From Autoimmune to Idiopathic Lung Fibrosis.

Samara KD, Trachalaki A, Tsitoura E, Koutsopoulos AV, Lagoudaki ED, Lasithiotaki I, Margaritopoulos G, Pantelidis P, Bibaki E, Siafakas NM, Tzanakis N, Wells AU, Antoniou KM.

Respir Res. 2017 Dec 29;18(1):218. doi: 10.1186/s12931-017-0692-9.

28.

Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema.

Jacob J, Bartholmai BJ, Rajagopalan S, Karwoski R, Nair A, Walsh SLF, Barnett J, Cross G, Judge EP, Kokosi M, Renzoni E, Maher TM, Wells AU.

Respirology. 2018 Jun;23(6):593-599. doi: 10.1111/resp.13231. Epub 2017 Dec 13.

29.

Unclassifiable-interstitial lung disease: Outcome prediction using CT and functional indices.

Jacob J, Bartholmai BJ, Rajagopalan S, Egashira R, Brun AL, Kokosi M, Nair A, Walsh SLF, Karwoski R, Nicholson AG, Hansell DM, Wells AU.

Respir Med. 2017 Sep;130:43-51. doi: 10.1016/j.rmed.2017.07.007. Epub 2017 Jul 14.

30.

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.

Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, Hansell DM, Inoue Y, Johkoh T, Nicholson AG, Knight SL, Raoof S, Richeldi L, Ryerson CJ, Ryu JH, Wells AU.

Lancet Respir Med. 2018 Feb;6(2):138-153. doi: 10.1016/S2213-2600(17)30433-2. Epub 2017 Nov 15. Review.

31.

Psychometric validation of the needs assessment tool: progressive disease in interstitial lung disease.

Johnson MJ, Jamali A, Ross J, Fairhurst C, Boland J, Reigada C, Hart SP, Grande G, Currow DC, Wells AU, Bajwah S, Papadopoulos T, Bland JM, Yorke J.

Thorax. 2018 Sep;73(9):880-883. doi: 10.1136/thoraxjnl-2017-210911. Epub 2017 Nov 17.

32.

An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study.

Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, Flynn A, Molyneaux PL, Braybrooke R, Divyateja H, Parfrey H, Rassl D, Russell AM, Saini G, Renzoni EA, Duggan AM, Hubbard R, Wells AU, Lukey PT, Marshall RP, Jenkins RG.

Lancet Respir Med. 2017 Dec;5(12):946-955. doi: 10.1016/S2213-2600(17)30430-7. Epub 2017 Nov 14.

33.

The Genomic Detection of Usual Interstitial Pneumonia from Transbronchial Biopsy Tissue: A Dress Rehearsal for the Future?

Wells AU, Antoniou KM.

Ann Am Thorac Soc. 2017 Nov;14(11):1632-1633. doi: 10.1513/AnnalsATS.201708-670ED. No abstract available.

PMID:
29090993
34.

Treatment doses in idiopathic pulmonary fibrosis: The devil is in the detail.

Wells AU, Antoniou KM.

Respirology. 2018 Mar;23(3):244-245. doi: 10.1111/resp.13182. Epub 2017 Oct 20. No abstract available.

35.

Idiopathic pulmonary fibrosis.

Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, Swigris JJ, Taniguchi H, Wells AU.

Nat Rev Dis Primers. 2017 Oct 20;3:17074. doi: 10.1038/nrdp.2017.74. Review.

PMID:
29052582
36.

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.

Flaherty KR, Brown KK, Wells AU, Clerisme-Beaty E, Collard HR, Cottin V, Devaraj A, Inoue Y, Le Maulf F, Richeldi L, Schmidt H, Walsh S, Mezzanotte W, Schlenker-Herceg R.

BMJ Open Respir Res. 2017 Sep 17;4(1):e000212. doi: 10.1136/bmjresp-2017-000212. eCollection 2017.

37.

Serial automated quantitative CT analysis in idiopathic pulmonary fibrosis: functional correlations and comparison with changes in visual CT scores.

Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Egashira R, Brun AL, Nair A, Walsh SLF, Karwoski R, Wells AU.

Eur Radiol. 2018 Mar;28(3):1318-1327. doi: 10.1007/s00330-017-5053-z. Epub 2017 Sep 29.

PMID:
28963678
38.

POINT: Should BAL Be Routinely Performed in the Diagnostic Evaluation of Idiopathic Pulmonary Fibrosis? Yes.

Wells AU, Kokosi MA.

Chest. 2017 Nov;152(5):917-919. doi: 10.1016/j.chest.2017.08.1173. Epub 2017 Sep 21. No abstract available.

PMID:
28943282
39.

Rebuttal From Drs Wells and Kokosi.

Wells AU, Kokosi MA.

Chest. 2017 Nov;152(5):922-923. doi: 10.1016/j.chest.2017.08.1176. Epub 2017 Sep 21. No abstract available.

PMID:
28943277
40.

Pleuroparenchymal Fibroelastosis: A Review of Histopathologic Features and the Relationship Between Histologic Parameters and Survival.

Khiroya R, Macaluso C, Montero MA, Wells AU, Chua F, Kokosi M, Maher TM, Devaraj A, Rice A, Renzoni EA, Nicholson AG.

Am J Surg Pathol. 2017 Dec;41(12):1683-1689. doi: 10.1097/PAS.0000000000000928.

41.

Evaluation of visual and computer-based CT analysis for the identification of functional patterns of obstruction and restriction in hypersensitivity pneumonitis.

Jacob J, Bartholmai BJ, Brun AL, Egashira R, Rajagopalan S, Karwoski R, Kouranos V, Kokosi M, Hansell DM, Wells AU.

Respirology. 2017 Nov;22(8):1585-1591. doi: 10.1111/resp.13122. Epub 2017 Jul 11.

PMID:
28699237
42.

Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis.

Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Maher TM, Nair A, Karwoski R, Renzoni E, Walsh SLF, Hansell DM, Wells AU.

Eur Respir J. 2017 Jul 5;50(1). pii: 1700379. doi: 10.1183/13993003.00379-2017. Print 2017 Jul.

PMID:
28679612
43.

Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?

Johannson KA, Strâmbu I, Ravaglia C, Grutters JC, Valenzuela C, Mogulkoc N, Luppi F, Richeldi L, Wells AU, Vancheri C, Kreuter M; Erice ILD Working Group.

Lancet Respir Med. 2017 Jul;5(7):591-598. doi: 10.1016/S2213-2600(17)30219-9. Review.

PMID:
28664861
44.

Effect of Emphysema Extent on Serial Lung Function in Patients with Idiopathic Pulmonary Fibrosis.

Cottin V, Hansell DM, Sverzellati N, Weycker D, Antoniou KM, Atwood M, Oster G, Kirchgaessler KU, Collard HR, Wells AU.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1162-1171. doi: 10.1164/rccm.201612-2492OC.

PMID:
28657784
45.

Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.

Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, Babalis D, Renzoni EA, Denton CP, Wells AU, Maher TM.

Trials. 2017 Jun 15;18(1):275. doi: 10.1186/s13063-017-2016-2.

46.

Update in Interstitial Lung Disease 2016.

Wells AU, Maher TM.

Am J Respir Crit Care Med. 2017 Jul 15;196(2):132-138. doi: 10.1164/rccm.201702-0351UP. No abstract available.

47.

Chronic hypersensitivity pneumonitis: identification of key prognostic determinants using automated CT analysis.

Jacob J, Bartholmai BJ, Egashira R, Brun AL, Rajagopalan S, Karwoski R, Kokosi M, Hansell DM, Wells AU.

BMC Pulm Med. 2017 May 4;17(1):81. doi: 10.1186/s12890-017-0418-2.

48.

Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial.

Visca D, Tsipouri V, Mori L, Firouzi A, Fleming S, Farquhar M, Leung E, Maher TM, Cullinan P, Hopkinson N, Wells AU, Banya W, Whitty JA, Adamali H, Spencer LG, Sestini P, Renzoni EA.

Trials. 2017 Apr 28;18(1):201. doi: 10.1186/s13063-017-1912-9.

49.

Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.

Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, Nicholson AG, Wells AU.

Arthritis Rheumatol. 2017 Aug;69(8):1670-1678. doi: 10.1002/art.40130. Epub 2017 Jul 18.

50.

A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective.

Ryerson CJ, Corte TJ, Lee JS, Richeldi L, Walsh SLF, Myers JL, Behr J, Cottin V, Danoff SK, Flaherty KR, Lederer DJ, Lynch DA, Martinez FJ, Raghu G, Travis WD, Udwadia Z, Wells AU, Collard HR.

Am J Respir Crit Care Med. 2017 Nov 15;196(10):1249-1254. doi: 10.1164/rccm.201702-0400PP. No abstract available.

PMID:
28414524

Supplemental Content

Loading ...
Support Center